Overview of the characteristics of the study population
| Factor | |
| Age (years), mean ±SD | 66.8±11.0 |
| Sex: male, n (%) | 1070 (53.9) |
| Diabetes duration (years), median (IQR) | 12 (10) |
| Microvascular complications present, n (%) | 865 (43.6) |
| Macrovascular complications present, n (%) | 828 (41.7) |
| Smoking: current smoker, n (%) | 261 (13.2) |
| Treated in primary care, n (%) | 1202 (60.6) |
| Country, n (%) | |
| Belgium | 199 (10.0) |
| France | 176 (8.9) |
| Germany | 364 (18.3) |
| Ireland | 189 (9.5) |
| Italy | 384 (19.4) |
| The Netherlands | 166 (8.4) |
| Sweden | 206 (10.4) |
| UK | 300 (15.1) |
| Diabetes education received, n (%) | 1498 (75.5) |
| Currently treated depression, n (%)* | 179 (11.3) |
| Health status (EQ-5D-VAS), mean±SD | 66±20 |
| DTSQ total score, mean±SD | 28.50±7.52 |
| DTSQ2: perceived hyperglycaemia, mean±SD | 2.64±1.85 |
| DTSQ3: perceived hypoglycaemia, mean±SD | 1.55±1.91 |
| Body mass index (kg/m2), mean±SD | 31±6 |
| Systolic blood pressure (mm Hg), mean±SD | 137±17 |
| HbA1c (%), mean±SD | 7.9±1.4 |
| HbA1c (mmol/mol), mean±SD | 62.6±14.9 |
| Fasting plasma glucose (mmol/L), mean±SD | 8.5±3.7 |
| Cholesterol (mmol/L), mean±SD | 4.6±1.2 |
| LDL cholesterol (mmol/L), mean±SD | 2.5±0.9 |
| Injection frequency, median (IQR) | 2 (3) |
| Insulin regimen, n (%) | |
| Basal | 603 (30.4) |
| Mix two times per day | 345 (17.4) |
| Basal–prandial | 709 (35.7) |
| Other | 327 (16.5) |
n=1984 for all factors except for ‘currently treated depression’.
*n=1768.
DTSQ, Diabetes Treatment Satisfaction Questionnaire; EQ-5D-VAS, EuroQol Five-Dimensions Questionnaire Visual Analogue Scale; HbA1c, glycated haemoglobin; LDL, low-density lipoprotein.